Cha Bundang Medical Center

Seongnam 13532

1 studies enrolling now · 5 studies all time

What they study most

Advanced Cholangiocarcinoma, FGFR2 Fusions, FGFR2 Gene Rearrangements, Gene Rearrangement, Locally Advanced Pancreatic Cancer, Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation, Metastatic Pancreas Cancer, Neoplasms, Pancreatic Adenocarcinoma

Studies at this site

• Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement — Recruiting now
• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation — Recruiting now
• A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer — Running, not enrolling
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early
• EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX — Completed